2011;64:401 406. 261. Cheng J, Zhang W, Zhang X, et al. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis. JAMA Intern Med. 2014;174: 773 785. 262. Bangalore S, Fakheri R, Toklu B, et al. Diabetes mellitus as a compelling indication for use of renin angiotensin system blockers: systematic review and meta-analysis of randomized trials. BMJ. 2016;352:i438. references www.kidney-international.org 263. Clase CM, Barzilay J, Gao P, et al. Acute change in glomerular ltration rate with inhibition of the renin-angiotensin system does not predict subsequent renal and cardiovascular outcomes. Kidney Int. 2017;91: 683 690. 264. Bandak G, Sang Y, Gasparini A, et al. Hyperkalemia after initiating renin- angiotensin system blockade: The Stockholm Creatinine Measurements (SCREAM) Project. J Am Heart Assoc. 2017;6:e005428. 265. Jun M, Jardine MJ, Perkovic V, et al. Hyperkalemia and renin-angiotensin aldosterone system inhibitor therapy in chronic kidney disease: A general practice-based, observational study. PLoS One. 2019;14: e0213192. 266. Spinowitz BS, Fishbane S, Pergola PE, et al. Sodium zirconium cyclosilicate among individuals with hyperkalemia: a 12-month phase 3 study. Clin J Am Soc Nephrol. 2019;14:798 809. 267. Weir MR, Bakris GL, Bushinsky DA, et al. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med. 2015;372:211 221. 268. Collard D, Brouwer TF, Peters RJG, et al. Creatinine rise during blood pressure therapy and the risk of adverse clinical outcomes in patients with type 2 diabetes mellitus. Hypertension. 2018;72:1337 1344. 269. Ku E, Ix JH, Jamerson K, et al. Acute declines in renal function during intensive BP lowering and long-term risk of death. J Am Soc Nephrol. 2018;29:2401 2408. 270. Schmidt M, Mans eld KE, Bhaskaran K, et al. 